Azithromycin compared with amoxicillin in the treatment of erythema migrans: A double-blind, randomized, controlled trial

Benjamin J. Luft, Raymond J. Dattwyler, Russell C. Johnson, Steven W. Luger, Elizabeth M. Bosler, Daniel W. Rahn, Edwin J. Masters, Edgar Grunwaldt, Shrikant D. Gadgil

Research output: Contribution to journalArticle

174 Scopus citations

Abstract

Objective: To determine whether azithromycin or amoxicillin is more efficacious for the treatment of erythema migrans skin lesions, which are characteristic of Lyme disease. Design: Randomized, double-blind, double-dummy, multicenter study. Acute manifestations and sequelae were assessed using a standardized format. Baseline clinical characteristics and response were correlated with serologic results. Patients were followed for 180 days. Setting: 12 outpatient centers in eight states. Patients: 246 adult patients with erythema migrans lesions at least 5 cm in diameter were enrolled and were stratified by the presence of flu-like symptoms (such as fever, chills, headache, malaise, fatigue, arthralgias, and myalgias) before randomization. Intervention: Oral treatment with either amoxicillin, 500 mg three times daily for 20 days, or azithromycin, 500 mg once daily for 7 days. Patients who received azithromycin also received a dummy placebo so that the dosing schedules were identical. Results: Of 217 évaluable patients, those treated with amoxicillin were significantly more likely than those treated with azithromycin to achieve complete resolution of disease at day 20, the end of therapy (88% compared with 76%; P = 0.024). More azithromycin recipients (16%) than amoxicillin recipients (4%) had relapse (P = 0.005). A partial response at day 20 was highly predictive of relapse (27% of partial responders had relapse compared with 6% of complete responders; P < 0.001). For patients treated with azithromycin, development of an antibody response increased the possibility of achieving a complete response (81% of seropositive patients achieved a complete response compared with 60% of seronegative patients; P = 0.043). Patients with multiple erythema migrans lesions were more likely than patients with single erythema migrans lesions (P < 0.001) to have a positive antibody titer at baseline (63% compared with 17% for IgM; 39% compared with 16% for IgG). Fifty-seven percent of patients who had relapse were seronegative at the time of relapse. Conclusions: A 20-day course of amoxicillin was found to be an effective therapeutic regimen for erythema migrans. Most patients were seronegative for Borrelia burgdorferi at the time of presentation with erythema migrans (65%) and at the time of relapse (57%).

Original languageEnglish (US)
Pages (from-to)785-791
Number of pages7
JournalAnnals of internal medicine
Volume124
Issue number9
DOIs
StatePublished - May 1 1996

    Fingerprint

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Luft, B. J., Dattwyler, R. J., Johnson, R. C., Luger, S. W., Bosler, E. M., Rahn, D. W., Masters, E. J., Grunwaldt, E., & Gadgil, S. D. (1996). Azithromycin compared with amoxicillin in the treatment of erythema migrans: A double-blind, randomized, controlled trial. Annals of internal medicine, 124(9), 785-791. https://doi.org/10.7326/0003-4819-124-9-199605010-00002